Vascular endothelial growth factor receptor-3 directly interacts with phosphatidylinositol 3-kinase to regulate lymphangiogenesis by Coso, Sanja et al.
This is the author’s version of a work that was submitted/accepted for pub-
lication in the following source:
Coso, Sanja, Zeng, Yiping, Opeskin, Kenneth, & Williams, Elizabeth D.
(2012) Vascular endothelial growth factor receptor-3 directly interacts with
phosphatidylinositol 3-kinase to regulate lymphangiogenesis. PLoS ONE,
7 (6), e39558-1.
This file was downloaded from: http://eprints.qut.edu.au/77758/
c© Copyright 2012 Coso et al.
This is an open-access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution,
and reproduction in any medium, provided the original author and source
are credited.
Notice: Changes introduced as a result of publishing processes such as
copy-editing and formatting may not be reflected in this document. For a
definitive version of this work, please refer to the published source:
http://dx.doi.org/10.1371/journal.pone.0039558
Vascular Endothelial Growth Factor Receptor-3 Directly
Interacts with Phosphatidylinositol 3-Kinase to Regulate
Lymphangiogenesis
Sanja Coso1, Yiping Zeng1, Kenneth Opeskin2,3, Elizabeth D. Williams1*
1Centre for Cancer Research, Monash Institute of Medical Research, Monash University, Melbourne, Victoria, Australia, 2Department of Pathology, University of
Melbourne, Parkville, Victoria, Australia, 3Department of Anatomical Pathology, St Vincent’s Hospital, Fitzroy, Victoria, Australia
Abstract
Background: Dysfunctional lymphatic vessel formation has been implicated in a number of pathological conditions
including cancer metastasis, lymphedema, and impaired wound healing. The vascular endothelial growth factor (VEGF)
family is a major regulator of lymphatic endothelial cell (LEC) function and lymphangiogenesis. Indeed, dissemination of
malignant cells into the regional lymph nodes, a common occurrence in many cancers, is stimulated by VEGF family
members. This effect is generally considered to be mediated via VEGFR-2 and VEGFR-3. However, the role of specific
receptors and their downstream signaling pathways is not well understood.
Methods and Results: Here we delineate the VEGF-C/VEGF receptor (VEGFR)-3 signaling pathway in LECs and show that
VEGF-C induces activation of PI3K/Akt and MEK/Erk. Furthermore, activation of PI3K/Akt by VEGF-C/VEGFR-3 resulted in
phosphorylation of P70S6K, eNOS, PLCc1, and Erk1/2. Importantly, a direct interaction between PI3K and VEGFR-3 in LECs
was demonstrated both in vitro and in clinical cancer specimens. This interaction was strongly associated with the presence
of lymph node metastases in primary small cell carcinoma of the lung in clinical specimens. Blocking PI3K activity abolished
VEGF-C-stimulated LEC tube formation and migration.
Conclusions: Our findings demonstrate that specific VEGFR-3 signaling pathways are activated in LECs by VEGF-C. The
importance of PI3K in VEGF-C/VEGFR-3-mediated lymphangiogenesis provides a potential therapeutic target for the
inhibition of lymphatic metastasis.
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Introduction
Lymph node status is an important factor used in determining
the stage of disease progression, a powerful predictor of patient
survival, and informs treatment decisions. Whilst lymph node
metastases are not directly responsible for cancer-related death,
they are indicators that tumor has developed a metastatic
phenotype. In addition, cancer cells may spread from the lymph
nodes to distant organs, where they can develop a secondary
tumor and perturb critical functions of that organ. Consistent with
this, improved patient survival is observed upon removal of
involved regional lymph nodes for a number of cancers [1–3].
Standard of care for solid tumors is the biopsy of the sentinel node
(first lymph node which receives lymphatic drainage from the
primary tumor) and, if indicated, extensive lymphadenectomy.
Entry of cancer cells into the lymphatic vasculature at the
primary tumor site may be facilitated by the higher permeability of
lymphatic vessels, and by the absence of a regular basement
membrane [4]. Until recently, the presence of lymphatic vessels
inside the tumor bulk was disputed [5,6] with studies showing that
peritumoral lymphatics are predominantly responsible for pro-
moting metastasis [7,8]. Furthermore, tumors can actively induce
the formation of lymphatic vessels - typically via release of vascular
endothelial growth factor (VEGF)-C or VEGF-D - and thereby
promote metastasis to draining lymph nodes [9,10].
Microvessel density, which includes both blood and lymphatic
vessels, is an indicator of biological aggressiveness and metastatic
potential in many types of solid tumors [11]. Intratumoral
lymphatic vessels and metastasis to lymph nodes and lungs have
been documented in mice bearing human tumor xenografts
expressing VEGF-C or VEGF-D [9,10], as well as in VEGF-C or -
D transgenic mouse tumors [12].
The exact mechanism by which VEGF receptor (VEGFR)
ligands increase tumor cell entry into lymphatic vessels is likely to
involve several biological processes. The ligands might increase the
surface area of functional lymphatics in the tumor margin, thus
providing more opportunity for a tumor cell to enter the
lymphatics and disseminate. Furthermore, VEGFR ligands may
stimulate tumor-associated lymphatics or the draining lymph
nodes to release chemotactic factors that recruit tumor cells to
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enter lymphatics, or they may directly affect tumor cells.
Lymphatic endothelial cells (LECs) are ideally positioned to play
a central role in the early steps of lymphangiogenesis as they
express VEGFRs and respond to ligand stimulation in vitro [13]
and in vivo [14].
VEGF-C is a primary regulator of lymphangiogenesis in
developmental and pathological conditions including tumor
lymphatic metastasis [15,16]. Moreover, the expression of
VEGF-C by tumor cells correlates with lymph node metastasis
in a variety of human cancers, indicating an important role of this
pathway in tumor progression (reviewed in [17]). VEGF-C binds
and activates two related receptor tyrosine kinases, VEGFR-2 and
VEGFR-3 [18], to induce lymphangiogenesis [19–21]. Despite the
importance of the VEGF-C/VEGFR-3 pathway in lymphangio-
genesis, its downstream signal transduction pathways have
remained relatively unexplored. Thus far studies in lymphatic
cancer metastasis have mostly investigated at VEGF-C/VEGFR-3
signaling pathways in the context of cancer cell signaling, such as
breast cancer cells [22] and squamous cells carcinoma of the head
and neck [23]. Because lymphatic vessels are an important
indicator of disease in metastatic cancers and an essential
treatment target, it is imperative to further explore the
downstream signaling pathways regulating primary LECs and in
lymphatic vessels associated with metastatic disease.
To delineate the signal transduction pathways involved in
VEGFR-3-mediated lymphangiogenesis, we investigated the
biological functions and signaling pathways stimulated by
VEGF-C in primary LECs. The results show that VEGF-C
stimulation induces distinct intracellular signaling pathway acti-
vation and biological responses in LECs. Only one study done by
Makinen et al. [20] has indicated the importance of PI3K
signaling in the growth and survival of VEGF stimulated LEC.
However, it has not been reported thus far whether there is a
direct interaction between PI3K and VEGFR-3 molecules in
LECs and more importantly, there have been no studies to show a
direct interaction of VEGFR-3/PI3K in isolated LECs nor
lymphatic vessels in situ. Importantly, we show here for the first
time that PI3K forms a complex with VEGFR-3 in isolated LECs,
and that this complex is readily detected in lymphatic vessels (in
addition to cancer cells) in lymph node metastatic small cell lung
carcinoma (SCLC) specimens. Thus, this signaling complex may
be a novel prognostic factor and suggests a critical role for PI3K in
VEGF-C/VEGFR-3 induced lymphangiogenesis.
Results
VEGF-C Induces PI3K-dependent Akt Activation via
VEGFR-3 in LECs
VEGF-C (at 100 and 200 ng/ml) significantly stimulated tube
formation in lung, dermal and prostatic LECs (Figure 1A).
VEGFR-2 and VEGFR-3 were abundantly expressed in LECs
isolated from all tissues examined (lung, dermis, prostate;
Figure 1B). As the PI3K/Akt signaling pathway has been reported
to be downstream of both VEGFR-2 and VEGFR-3 [24,25], we
investigated the effect of different VEGFR ligands on Akt
activation in a panel of prostatic LECs. VEGF-C, but not other
VEGFR ligands, rapidly stimulated Akt phosphorylation at Ser473
(Figure 2A) in a time- and concentration-dependent manner
(Figure 2B & C). VEGF-C-induced Akt phosphorylation was
readily detectable following 5 minutes of treatment, with maximal
phosphorylation reached after 15 minutes. Akt phosphorylation
remained above control levels 120 minutes post VEGF-C
(100 ng/ml) treatment (Figure 2B). VEGF-C156S, the VEGF-C
mutant form which only activates VEGFR-3, also induced
phosphorylation of Akt at high concentrations (Figure 2C). By
contrast VEGF-A, which can activate both VEGFR-1 and
VEGFR-2 (see Figure S1 for assessment of specificity), and
VEGF-E, a VEGFR-2 specific ligand, did not activate Akt in
LECs (Figure 2A).
As both VEGFR-2 and VEGFR-3 are receptors for VEGF-C,
we sought to further define which receptor was involved in VEGF-
C-induced Akt phosphorylation in LECs. Blocking VEGFR-3
using neutralizing antibody hF4-3C5 reduced VEGF-C-induced
Akt activation to baseline levels. Neutralizing antibodies against
either VEGFR-1 or VEGFR-2 had no effect on phospho-Akt
levels (Figure 2D). Simultaneous inhibition of both VEGFR-3 and
Figure 1. VEGF-C induces LEC tube formation. A, Prostatic LEC
tube length at 4.5 hours post VEGF-C treatment was quantified using
ImageJ. VEGF-C significantly increased the number of tubes formed
compared to vehicle control. Data expressed as mean6s.e.m., n = 3,
***P,0.001 using One-way ANOVA, Bonferroni post-analysis. B, Western
blotting analysis of VEGFR-2 and VEGFR-3 expression in lung, neonatal
dermis and prostate LECs. b-tubulin was used as a loading control.
doi:10.1371/journal.pone.0039558.g001
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Figure 2. VEGF-C induces PI3K-dependent Akt phosphorylation via VEGFR-3 in LECs. A, Western blotting analysis of phosphorylated Akt
(S473) in prostatic LECs following a 15 minute ligand stimulation: VEGF-A (100 ng/ml), VEGF-C (100 ng/ml), VEGF-C156S (250 ng/ml), VEGF-D (250 ng/
ml) and VEGF-E (100 ng/ml). B, Time course for Akt phosphorylation (S473) in LECs after VEGF-C (100 ng/ml) stimulation. C, Concentration-dependent
phosphorylation of LEC Akt (S473) following 15 minute stimulation with VEGF-C or VEGF-C156S. D, Effect of inhibition of VEGFR-3 (hF4-3C5), VEGFR-2
(IMC-1121b) or VEGFR-1 (IMC-18F1) on LEC Akt (S473) phosphorylation in response to VEGF-C (100 ng/ml). E, Effect of inhibition of PI3K (AS252424,
LY294002) or Raf/MEK (PD98059) on Akt (S473) phosphorylation in LECs in response to VEGF-C (100 ng/ml). Serum-free vehicle treated LEC lysate is
indicated by ‘09 in all blots. n = 3. Densitometry analysis is shown for each blot either italicized or graphed; where integrated intensity of
phosphorylated molecules was firstly compared to that of the total target protein for each sample, and then expressed as fold increase in integrated
VEGFR-3-PI3K Interaction in Lymphangiogenesis
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VEGFR-2 did not further increase the inhibition compared to
blocking VEGFR-3 alone (Figure 2D). Thus VEGF-C activates
Akt via VEGFR-3 in LECs. As Akt is a well documented
downstream target of PI3K [26], we examined whether VEGF-C/
VEGFR-3-induced Akt activation was PI3K dependent. The
PI3K inhibitors LY294002 and AS252424, but not MEK1
inhibitor PD98059, abolished VEGF-C-induced Akt phosphory-
lation (Figure 2E), demonstrating that VEGF-C/VEGFR-3
mediates Akt phosphorylation via PI3K.
P70S6K, eNOS and PLCc, but not mTOR, are Activated by
VEGF-C Signaling through VEGFR-3
To identify the pathways downstream of Akt activation in
response toVEGF-C, we examined the effects of VEGFR ligands on
the activation of P70S6K and mammalian target of rapamycin
(mTOR) in LECs. Phosphorylation of P70S6K was detected in
LECs stimulated by VEGF-C (100 ng/ml), but not other members
of VEGFR family (Figure 3A, top left). VEGF-C induced P70S6K
phosphorylation in a concentration- and time-dependent manner,
with maximal phosphorylation reached after 30 minute treatment
(Figure 3A, top right). This stimulation pattern is similar to that of
VEGF-C-induced Akt phosphorylation in LECs (Figure 2B & C),
although P79S6K phosphorylation levels returned to baseline more
quickly. Inhibition of VEGFR-3, but not VEGFR-1 or VEGFR-2,
abolished VEGF-C-induced P70S6K phosphorylation (Figure 3A,
bottom left). The highly selective PI3Kc inhibitor AS252424, whose
half-maximal inhibitory concentration (IC50) for isoform c is over
200 times lower than that of LY294002 [27], decreased P70S6K
phosphorylation in response to VEGF-C. By contrast, non-selective
PI3K inhibitor LY294002 did not block VEGF-C-induced phos-
phorylation of P70S6K (Figure 3A, bottom right). These results
suggest that PI3Kc, rather than the other PI3K isoforms, is involved
inVEGF-C-stimulated P70S6Kphosphorylation. By contrast, none
of the VEGFR ligands investigated altered the phosphorylation
status of mTOR in LECs (Figure S2A). Together, these results show
that VEGF-C activates stimulation of the VEGFR-3/PI3K/Akt/
P70S6K pathway in LECs.
Akt activation also induces endothelial nitric oxide synthase
(eNOS) phosphorylation in blood vascular endothelial cells in
response to VEGF-A and VEGF-C [28,29]. We determined the
effect of VEGF-C on eNOS activation in LECs. Both VEGF-C
and VEGF-D strongly phosphorylated eNOS at Ser1177
(Figure 3B, top left). By contrast, VEGF-A, VEGF-E and
VEGF-C156S had only very weak effects on the phosphorylation
of eNOS in LECs (Figure 3B, top left). VEGF-C induced eNOS
phosphorylation at Ser1177 in a concentration- and time-
dependent manner, with a maximal phosphorylation reached
after 15 minutes of treatment (Figure 3B, top right). Inhibition of
VEGFR-3, but not VEGFR-1 or VEGFR-2, reduced VEGF-C-
induced eNOS Ser1177 phosphorylation (Figure 3B, bottom left).
The PI3K inhibitors LY294002 and AS252424, but not the Raf/
MEK inhibitor PD98059, abolished VEGF-C-induced eNOS
Ser1177 phosphorylation in a concentration-dependent manner
(Figure 3B, bottom right). VEGF-C stimulation induced the
phosphorylation of Erk1/2 in LECs (Figure S2B-G). PD98059
diminished, but did not completely block VEGF-C-induced Erk1/
2 phosphorylation in a dose-dependent manner (Figure S2D)
indicating that Raf/MEK regulation of VEGF-C induced Erk
phosphorylation may be indirect. PD98059 had no effect on
VEGF-C-induced Akt phosphorylation (Figure 2E), indicating the
specificity of this inhibitor to MAPK in LECs. At least two
upstream pathways have been implicated in Raf/MEK/Erk
activation including protein kinase C (PKC) and Ras [30]. To
determine whether PKC is involved in Erk activation in primary
LECs, cells were pretreated with a PKC inhibitor GF109203X
prior to VEGF-C stimulation. GF109203X blocked VEGF-C-
induced Erk1/2 activation dose-dependently (Figure S2D), indi-
cating PKC mediates VEGF-C/VEGFR-3-induced Raf/MEK/
Erk activation in LECs. The specificity of the inhibitory effect of
GF109203X on PKC in LECs was confirmed by a lack of effect on
Akt activation in LECs (data not shown). To address whether
PI3K is involved in VEGF-C-induced Erk activation, LECs were
pretreated with the PI3K inhibitor AS252424 prior to VEGF-C
stimulation (Figure S2D). Our data shows that VEGF-C/VEGFR-
3 interaction stimulates eNOS phosphorylation in LECs via the
PI3K/Akt pathway.
The PI3K and phospholipase Cc (PLCc) pathways are
interconnected. PLCc is known to be involved in a number of
tyrosine kinase signaling pathways, including the VEGF-A/
VEGFR-2 cascade [31–33]. To address whether PLCc is involved
in the VEGF-C signaling pathway and whether this is dependent
on isoform PLCc1 or PLCc2 [34], LECs were treated with various
concentrations of VEGF-C for 15 minutes and PLCc phosphor-
ylation assessed. As shown in Figure 3C (top left), VEGF-C
stimulated PLCc1 phosphorylation at tyrosine 783 in a concen-
tration-dependent manner, whereas it had no effect on the
phosphorylation of PLCc2 at either tyrosine 1217 or tyrosine 759
(Figure 3C, bottom left). Maximal phosphorylation of PLCc1 was
reached after a 15 minute stimulation with VEGF-C, and declined
rapidly (Figure 3C, top left). Blocking VEGFR-3 inhibited VEGF-
C-induced PLCc1 phosphorylation (Figure 3C, bottom right).
These results show that VEGF-C phosphorylates PLCc1 via
VEGFR-3 in LECs. A direct physical association of VEGFR-3
with PLCc1 was not detected using co-immunoprecipitation (data
not shown). As PLCc1 has been reported to be a PI3K
downstream target [35], we investigated whether VEGF-C/
VEGFR-3 induced LEC PLCc1 phosphorylation is PI3K
dependent by pretreating LECs with PI3K inhibitor prior to
VEGF-C stimulation. The selective PI3Kc inhibitor AS252424
decreased VEGF-C-induced PLCc1 phosphorylation (Figure 3C,
top right), whereas the non-selective PI3K inhibitor LY294002
had no effect. On the other hand, silencing PLCc in LECs using
siRNA had no effect on VEGF-C-induced Akt phosphorylation
(Figure S3). Together, these results demonstrate the involvement
of PI3Kc in LEC PLCc1 activation in response to VEGF-C
stimulation, whereas VEGF-C-induced Akt phosphorylation is not
dependent on PLCc1.
Blocking PI3K Inhibits VEGF-C-induced LEC Tube
Formation and Migration
To investigate the functional role of PI3K/Akt, PLCc and Raf/
MEK/Erk pathways in VEGF-C/VEGFR-3-induced lymphan-
giogenesis, we examined the effect of inhibiting these pathways on
VEGF-C-induced LEC tube formation. As shown in Figure 4A, a
neutralizing antibody against VEGFR-3 (hF4-3C5) reduced
VEGF-C-induced capillary-like network formation in LECs to
basal levels, demonstrating VEGF-C induces LEC differentiation
and migration via VEGFR-3. Similarly, inhibition of PI3K/Akt
density compared to VEGF-C treated control samples. P value calculated using one-way ANOVA. For panels A-B data is compared to time-point zero;
panels D-E data is compared to VEGF-C treated control, except where indicated for serum free/VEGF-C treatment comparison. Columns: mean; bars:
s.e.m.; P,0.05 (*), P,0.01 (**); P,0.001 (***).
doi:10.1371/journal.pone.0039558.g002
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Figure 3. VEGF-C induces PI3Kc-dependent P70S6K (A), eNOS (B), and PLCc1 (C) phosphorylation via VEGFR-3 in LECs. Western
blotting analysis of phosphorylated P70S6K (A, top left) and eNOS (S1177) (B, top left) in prostatic LECs following 15 minute stimulation with ligand:
VEGF-C (100 ng/ml), VEGF-A (100 ng/ml), VEGF-C156S (250 ng/ml), VEGF-D (250 ng/ml) and VEGF-E (100 ng/ml). Time- and concentration-dependent
VEGFR-3-PI3K Interaction in Lymphangiogenesis
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activity suppressed VEGF-C-induced LEC tube formation to basal
levels. PLCc inhibition had a profound effect, almost completely
inhibiting all tube formation. By contrast, the Raf/MEK inhibitor
had no effect on LEC tube formation induced by VEGF-C
(Figure 4A). These data show that VEGF-C/VEGFR-3-induced
LEC capillary-like structure formation depends on PI3K/Akt and
PI3K/PLCc pathways, but not the Raf/MEK/Erk pathway.
We also determined the role of PLCc, PI3K/Akt and Raf/
MEK/Erk pathways in VEGF-C-induced LEC migration. As
shown in Figure 4B, VEGF-C significantly stimulated LEC
migration (P,0.001). Pharmacological inhibition of either
PI3K/Akt, Raf/MEK/Erk or PLCc blocked VEGF-C-induced
LEC migration in a concentration-dependent manner (Figure 4B,
left panel). Moreover, silencing PLCc1 in LECs using siRNA
significantly reduced VEGF-C-induced LEC migration (Figure 4B,
right panel). These results indicate that PI3K/Akt, PI3K/PLCc1,
and Raf/MEK/Erk pathways are involved in VEGF-C-induced
LEC migration.
VEGFR-3 and PI3K Form a Complex
Due to the critical role of PI3K in all VEGFR-3-mediated
pathways, we determined the interactions between VEGFR-3 and
PI3K using a co-immunoprecipitation strategy. As shown in
Figure 5A, there was direct association between total VEGFR-3
and PI3K subunit in LECs irrespective of ligand stimulation,
indicating that this association was constitutive under tissue culture
conditions.
To further extend this finding, we employed in situ proximity
ligation assay (PLA), which is highly specific and sensitive in
depicting close proximity of cellular molecules [36]. A significant
increase in VEGFR-3/phosphoPI3K interactions was detected in
LECs treated with VEGF-C when compared to vehicle control
(Figure 5B). No interaction signals were detected in negative
controls, which included the use of isotype control IgGs (Figure 5B)
and omission of one or both of the primary antibodies (data not
shown).
phosphorylation of P70S6K (A, top right), eNOS (S1177) (B, top right), and PLCc1 (Tyr783) (C, top left) in LECs in response to VEGF-C. The effect of
inhibition of VEGFR-3 (hF4-3C5), VEGFR-2 (IMC-1121b) or VEGFR-1 (IMC-18F1) on phosphorylation of P70S6K (A, bottom left), eNOS (S1177) (B, bottom
left); and VEGFR-3 (hF4-3C5) on PLCc1 (Tyr783) (C, bottom right) on LEC response to VEGF-C (100 ng/ml). The effect of AS252424, LY294002, PD98059,
and U-73122 on phosphorylation of P70S6K (A, top right), eNOS (S1177) (B, bottom right), and PLCc1 (Tyr783) (C, bottom right) on LECs in response to
VEGF-C. The effect of VEGF-C on phosphorylation of PLCc2 (Tyr759, Tyr1217) in LECs (C, bottom left). Control serum-free vehicle treated LEC lysate is
indicated by ‘09 in all blots. n = 3. Densitometry analysis is shown under each blot in italics; where integrated intensity of phosphorylated molecules
was firstly compared to that of the total target protein for each sample, and then expressed as fold change in integrated density compared to either
serum-free (A, top left and right panels; B, top left and right panels; C, top and bottom left panels) or VEGF-C treated control samples (A, bottom left and
right panels; B, bottom left and right panels; C, bottom and bottom left panels).
doi:10.1371/journal.pone.0039558.g003
Figure 4. Blocking PI3K inhibits VEGF-C-induced LEC tube formation and migration. Effect of anti-VEGFR-3 antibody (hF4-3C5, 20 mg/ml),
selective PI3Kc inhibitor (AS252424, 5 mM), Raf/MEK inhibitor (PD98059, 5 mM) and PLCc1 inhibitor (U-73122, 1 mM) on VEGF-C-induced (200 ng/ml)
LEC tube formation (A) and migration (B, left panel). Effect of PLCc1 siRNA or non-targeting control (NTC) on LEC VEGF-C-induced migration (B, right
panel). Control serum-free (with DMSO as appropriate) LEC is indicated by ‘09. *P,0.05, **P,0.01, ***P,0.001, compared to VEGF-C treated cells/NTC.
n = 3. Data shown as mean6s.e.m.
doi:10.1371/journal.pone.0039558.g004
VEGFR-3-PI3K Interaction in Lymphangiogenesis
PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e39558
VEGFR-3/PI3K Complexes Distinguish Lymph Node
Metastatic Small Cell Lung Cancers from Non-metastatic
Tumors
We next used in situ PLA to investigate the interactions between
VEGFR-3 and PI3K in human tumors. PLA VEGFR-3/PI3K
signals were significantly higher in lymphatic vessels of primary
small cell lung carcinomas from patients with lymph node
metastatic tumors (Figure 6A, C) when compared to patients with
non-metastatic tumors (Figure 6B, C). PLA VEGFR-3/PI3K
signals were also detected in cancer cells surrounding the
lymphatic vessels in the metastatic samples (Figure 6A, top and
bottom panels), whereas in non-metastatic samples they were
detected mostly in cells distant to the lymphatic vessels (Fig, 6B,
right bottom panel), but rarely in those containing within or
surrounding the non-metastatic lymphatic vessels (Figure 6B, top
right panel). The VEGFR-3/PI3K interaction was also observed in
lymphatic vessels (and the tumor cells) of lymph node metastatic
melanoma, breast and colon tissue (Figure 7). These results suggest
that VEGFR-3/PI3K p85 complex formation indicates ‘‘tumor
activated’’ lymphatic endothelium in vivo.
Discussion
Activation of the PI3K pathway is a common observation in
human tumors (reviewed in [37,38]). We have shown here for the
Figure 5. Direct interaction between PI3K p85 and VEGFR-3. A, LEC whole cell lysate was immunoprecipitated with anti-PI3K or isotype
control IgG followed by Western blotting of phospho-tyrosine (p-Tyr), VEGFR-3 or PI3K. LECs were treated with vehicle control (serum-free media ‘09),
IgG control, VEGF-C (100 ng/ml, C) or VEGF-A (100 ng/ml, A) ligand for 15 minutes. Control untreated LEC whole cell lysate is indicate by ‘WCL’ and
Jurkat cell lysate served as a positive control (Jurkat). B, Detection of VEGFR-3/phospho-PI3K complexes (red spots) in vitro in LECs grown in absence
(B, upper left panel) or presence (B, upper middle panel) of VEGF-C (100 ng/ml) for 15 minutes; CD31 staining (green); DAPI (blue); isotype IgG control in
PLA (B, upper right panel); quantification of VEGFR-3/phospho-PI3K and VEGFR-3/total-PI3K PLA signals using Olink Imaging Software (B, lower panel).
Data shown as mean6s.e.m. **P,0.01 using t-test analysis. n = 3. Bar = 50 mm.
doi:10.1371/journal.pone.0039558.g005
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Figure 6. Direct interaction between PI3K p85 and VEGFR-3 in metastatic small cell lung carcinoma. VEGFR-3/PI3K complexes (red)
detected by in situ PLA in lung tumor area and lymphatic vessels (green, podoplanin). Lymphatic vessel VEGFR-3/PI3K signals (red) and their
representative co-staining with podoplanin (green) in metastatic (A, top and middle panel, respectively) and non-metastatic (B, top and middle panel,
respectively) in small cell lung cancer tissue. VEGFR-3/PI3K signals were detected in cancer cells surrounding the lymphatic vessels in the metastatic
samples (A, top and bottom panel) as well as the lymphatic vessels; whereas the low signal in non-metastatic samples was detected mostly away from
the lymphatic vessels (B, bottom panel), and not in tumor cells inside or surrounding the non-metastatic lymphatic vessels (B, top and middle panels).
Bar, 25 mm. DAPI (blue); C. Quantification of PLA signals (at least 5 different regions in each sample) in the lymphatic vessels (LV) (C, left) in lymph node
VEGFR-3-PI3K Interaction in Lymphangiogenesis
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first time PI3K is directly associated with VEGFR-3 in LECs in
both isolated cells and human tumors. In the current study, we
used primary LECs to dissect the VEGF-C/VEGFR-3 signaling
pathway. VEGF-C selectively promoted tube formation in LECs
via activation of two classic signaling pathways, PI3K/Akt and
PLCc consistent with a previous study [20]. Interestingly, VEGF-
E (VEGFR-2 specific ligand) stimulation induced the phosphor-
ylation of Erk1/2 in LECs, but had no effect on the activation of
Akt or its downstream targets P70S6K or eNOS, despite the
expression of VEGFR-2 in LECs. Taken together, these results
reflect distinct biological responses to growth factor stimulation
that is specific the ligand. The molecular basis for this remains to
be determined.
The serine/threonine protein kinase Akt is a critical molecule in
the cellular signaling pathways leading to angiogenesis [39,40].
However, little is known about its role in lymphangiogenesis. In
this study we demonstrated in LECs that VEGF-C binding to its
receptor VEGFR-3 induced activation of Akt via PI3K. By
contrast, VEGF-A stimulation had a much lesser effect on Akt
phosphorylation despite the expression of its cognate receptor,
reported also in a recent study by Dellinger et al. [33]. The Akt
pathway was also shown to be important for survival, growth and
migration of human microvascular endothelial cells by Makinen et
al. [20].
We also found that P70S6K and eNOS serve as downstream
targets of the PI3K/Akt pathway in response to VEGF-C. VEGF-
A induced a small increase in eNOS (in line with Lahdernanta et
al. [41]), as well as P70S6K expression (which has not been shown
before). Kobayashi et al. [42] have demonstrated VEGF-C
mediated P70S6K/mTOR inhibitor rapamycin leads to reduction
of lymphatic metastasis using lymphatic metastasis-prone murine
pancreatic tumor cells. We show here for the first time the
importance of PI3K/Akt/P70S6K/eNOS pathway in regulating
lymphangiogenic properties in LECs.
In addition, we showed for the first time a physical interaction
between VEGFR-3 and PI3K in LECs that was independent of
ligand (VEGF-C) stimulation. In clinical specimens VEGFR-3/
PI3K interaction was associated with lymph node metastasis
suggesting that this complex may play a critical role in tumor-
induced lymphangiogenesis and thus the subsequent development
of lymph node metastasis.
Blocking PI3K abolished VEGF-C-stimulated LEC tube
formation and migration, demonstrating that the PI3K/Akt
signaling pathway plays a central role in LEC differentiation and
migration induced by VEGF-C/VEGFR-3, possibly via substrates
such as P70S6K and/or eNOS. Consistent with this, a central role
for the PI3K/Akt pathway has also been demonstrated in LEC
tube formation stimulated by the non-VEGF family lymphangio-
genic factors fibroblast growth factor-2 (FGF-2) and endothelin-1
[43]. Furthermore, eNOS has recently been reported to serve as a
mediator of VEGF-C-induced lymphangiogenesis [44]. In rat
LECs, FGF-2 stimulated tube formation is mediated by the PI3K/
mTOR pathway [45].
Taken together, the signaling pathway results show that
activation of discrete intracellular signaling pathways results in
specific biological responses in LECs. The exact molecular basis
underpinning how each ligand generates a specific biological
response in LECs remains to be determined. In addition, we
demonstrate that PI3K/Akt/P70S6K, PI3K/Akt/eNOS, PI3K/
PLCc1 and PI3K/Raf/MEK/Erk are important downstream
pathways for VEGF-C/VEGFR-3 signaling as each plays a role in
LEC migration.
Our finding of elevated numbers of VEGFR-3/PI3K complexes
in lymph node metastatic SCLC compared to organ confined
samples, raises the possibility that measurement of signaling
negative (LN-; n = 7; two samples were excluded because there were no lymphatic vessels present in the sections examined) and lymph node positive
(LN+; n = 10) samples using Olink Imaging Software. Plotted are mean values for individual patients. Line represents median value. *P,0.05.
doi:10.1371/journal.pone.0039558.g006
Figure 7. Direct interaction between PI3K p85 and VEGFR-3 in
metastatic melanoma (A), breast (B) and colon (C) cancers. PI3K
p85/VEGFR-3 complexes (red) detected by in situ PLA in tumor cells and
lymphatic vessels (green, podoplanin). Bar, 50 mm. Nuclei stained with
DAPI (blue).
doi:10.1371/journal.pone.0039558.g007
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complexes such as VEGFR-3/PI3K interaction may be useful
prognostic markers. There is currently limited data on the
significance of the VEGF family in lymphatic vessels in metastatic
SCLC, and our study provides the first evidence of the existence of
VEGFR-3/PI3K in both tumor cells and lymphatic vessels. Tanno
et al. [46] showed that SCLC tumor cells express functional
VEGFR-2 and VEGFR-3. In non-small cell lung carcinoma
(NSCLC) increased levels of VEGF-C and VEGF-D have been
shown to correlate with lymphatic invasion and lymph node
metastasis in patient samples [47,48]. Arinaga et al. [49] have
shown that NSCLC patients with tumors positive for VEGF-C
and VEGFR-3 expression had decreased survival rates. An
interesting study from Renyi-Vamos et al. [50] found that
lymphangiogenesis in NSCLC negatively correlated with patient
survival, but only in nonangiogenic tumors. These tumors mainly
co-opt host tissue lymphatics during their growth, in contrast to
the majority of angiogenic tumors in which expansion is associated
with a concomitant lymphangiogenesis.
PI3K pathway inhibitors are just entering the clinic for cancer
treatment of cancers following their success in pre-clinical murine
models. The efficacy of PI3K inhibitors is generally attributed to a
direct effect on cancer cells [51]. Our study indicates that targeting
the PI3K pathway in the context of the lymphangiogenic pathway
(VEGFR-3) may provide additional clinical benefit via the
inhibition of lymph node metastasis. Further elucidation of the
exact role of PI3K downstream targets in lymphangiogenesis in vivo
will lead to a better understanding of the molecular mechanisms
involved and will provide avenues for the development of potential
therapeutic drugs and combinational approaches targeting path-
ological lymphangiogenesis.
Materials and Methods
Ethics Statement
These studies were conducted with ethical approval of the St.
Vincent’s Hospital Human Research Ethics Committee HREC-A
and Monash University Standing Committee on Ethics in
Research Involving Humans, and in accordance with Australian
National Health and Medical Research Council Guidelines.
Written informed consent for the collection of fresh tissue and
generation of cell lines was obtained. Informed consent was waived
by the Ethics committee for the archival tissues used for
immunohistochemical analyses as these were used anonymously.
Reagents
Neutralizing antibodies specific to human VEGFR-1 (IMC-
18F1), human VEGFR-2 (IMC-1121b), and human VEGFR-3
(hF4-3C5) were obtained from ImClone (NY). Antibodies against
phosphorylated proteins P70S6K (Thr389, Clone: 1A5, Cat.
no. 9206), mTOR (Ser2448, Cat. no. 2971), eNOS (Ser1177;
Clone: C9C3, Cat. no. 9570), PLCc1 (Tyr783; Cat. no. 2821),
PLCc2 (Tyr1217; Cat. no. 3871), PLCc2 (Tyr759; Cat. no. 3874),
Erk1/2 (Thr202/Tyr204; Cat no. 9101), Tyr-100 (Cat. no. 9411)
and Akt (Ser 473; Cat. no. 9271S) were purchased from Cell
Signaling Technology (MA). Antibodies against total P70S6K
(Clone: 49D7, Cat. no. 9208), mTOR (Cat. no. 2972), eNOS
(Clone: 49G3, Cat. no. 9586), PLCc1 (Clone: D9H10, Cat.
no. 5690), PLCc2 (Cat. no. 3872), Erk1/2 (Clone: 137F5; Cat.
no. 4695), and Akt (Cat. no. 9272) were purchased from Cell
Signaling Technology (MA). The other antibodies used were: anti-
phospho PI3K p85 (Tyr458/p55 Tyr199; Cat. no. 4228; Milli-
pore, MA) and total PI3K p85 (Cat. no. 06–19; Millipore); mouse
anti-human CD31 (Clone: JC70A, Cat. no. M0823; DAKO,
Denmark); mouse anti-human podoplanin (Clone: D2-40, Cat.
no. 730-23; Signet Laboratories, MA); mouse anti-human
VEGFR-2 (Cat. no. AF357; R&D Systems, MN), goat anti-
human VEGFR-3 (Cat. no. AF349; R&D Systems); mouse anti-
human pan-actin (Clone: Ab-5, NeoMarkers, CA); Alexa Fluor
488- and 568-conjugated secondary antibodies (Invitrogen, CA),
and IRDye700DX conjugated anti-mouse IgG and IRDye800CW
conjugated anti-rabbit IgG (Rockland Immunochemicals, PA).
Recombinant human VEGF-A165 (Cat. no. 293-VE), VEGF-C
(Cat. no. 2179-VC), VEGF-C Cys156Ser (Cat. no. 752-VC/CF),
VEGF-D (Cat. no. 622-VD) and hepatocyte growth factor (HGF;
Cat. no. 294-HG) were purchased from R&D Systems.
LY294002 and GF109203X were purchased from Calbiochem
(CA). AS252424 and U-73122 were purchased from Alexis
Biochemicals (NY). PD98059 was purchased from Cayman
Chemical (MI).
Jurkat cell lysate was purchased from Millipore.
Clinical Specimens
Archival formalin-fixed paraffin-embedded tissue blocks were
retrieved from the St. Vincent’s Pathology archive for 19 patients
diagnosed with small cell lung carcinoma (SCLC). Nine specimens
were from patients with organ-confined disease, while the
remaining ten specimens were from patients with lymph node
metastases (median number of positive nodes 4.0, range 1–29).
The patient characteristics are described in Table S1, and no
statistically significant differences were observed between the two
cohorts. Original diagnoses were confirmed on hematoxylin and
eosin stained sections at the Department of Pathology, St.
Vincent’s Hospital, Melbourne. Melanoma, colon and breast
cancer specimens were also obtained from St. Vincent’s Hospital,
Melbourne.
Cell Culture
Primary LECs were isolated from human prostate tissue and
characterized as previously described [13]. Pure (.99.9%) LEC
populations from the sub-confluent primary cultures were
achieved using the CD34 and CD31 combined selection method
as previously described [13] (Figure S4). Primary neonatal human
dermal LECs [52] and primary human lung LECs [53] were
purchased from Lonza (Switzerland) and maintained in EGMTM-2
MV medium (Lonza). LECs between passages 3 and 6 were used
for the experiments described herein. Cells were routinely tested
for mycoplasma using the MycoAlert Mycoplasma Detection kit
(Lonza), and were always negative.
LEC Treatment, Immunoprecipitation, and Western
Blotting Analyses
LECswere plated in 12-well plates at a density of 105 cells per well
in EGMTM-2 MV medium. After overnight attachment, cells were
serum-starved (4 hours) and stimulated as indicated. The following
growth factors were tested: VEGF-A (25–400 ng/ml), VEGF-C
(25–400 ng/ml), VEGF-C156S (100–1600 ng/ml), VEGF-D
(250 ng/ml) and VEGF-E (25–400 ng/ml). For blocking experi-
ments, cells were pretreated for 1 hour with LY294002 (5–20 mM),
AS252424 (2.5–20 mM), U-73122 (0.1–10 mM), PD98059 (2.5–
10 mM), IMC-18F1 (5–20 mg/ml), IMC-1121b (5–20 mg/ml), or
hF4-3C5 (5–20 mg/ml) prior to ligand stimulation. The neutralizing
activity of IMC-1121b, and the lack of effect of hF4-3C5, on
inhibition of total and phospho-VEGFR-2 were confirmed by
western blotting analysis (Figure S1). Dimethylsulfoxide (DMSO), in
which the inhibitors were dissolved, was used as vehicle control.
After stimulation, cells were lysed in radioimmuno precipitation
assay (RIPA buffer) (Cat. no. 89900, Thermo Scientific, CA)
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containing protease (Cat. no. 78410, Thermo Scientific) and
phosphatase inhibitors (Cat. no. 78420, Thermo Scientific). For
immunoprecipitation, equal amounts of whole cell lysate were
incubated with anti-PI3K p85 or isotype IgG and protein pulled
down using Protein A/G Plus-agarose beads (Santa Cruz, CA).
Protein samples were separated by SDS-PAGE, transferred to
nitrocellulose and immunoblotted with the antibodies indicated.
Signals were visualized using an Odyssey Infrared Imaging System
(LI-COR Biosciences, NE). Densitometry analyses of Western
blotting results were performed using Odyssey software. Integrated
intensity of phosphorylatedmolecules was firstly compared to that of
the total target protein for each sample, and then expressed as fold
increase in integrated density compared to VEGF-C treated control
samples.
The experiments were performed using primary human lung,
neonatal skin and prostate LECs, as well as Jurkat cells.
Knockdown of PLCc1 in LECs Using siRNA
The siRNA ON-TARGETplus SMARTpool PLCc1 and the
siRNA nonspecific control were obtained from Dharmacon (CO).
LECs were plated in a 6-well plate and cultured for 24 hours to
50–60% confluence. Cells were transfected with 100 nM siRNA
using LipofectamineTM2000 (Invitrogen) as per the manufacturer’s
protocol. VEGF-C stimulation and migration assays were
performed 72 hours after siRNA transfection. The degree of
knockdown was determined using parallel samples for protein
analysis.
Tube Formation Assay
LEC tube formation assays were performed using growth factor
reduced (GFR) MatrigelTM (BD Biosciences) as previously
described [13]. Growth factors, inhibitors or neutralizing antibod-
ies were added at the start of the experiment. The reagents used
were VEGF-A (50–200 ng/ml), VEGF-C (50–200 ng/ml), and
anti-VEGFR-3 antibody (20 mg/ml). Images from all tube
formation experiments were digitally captured using an inverted
microscope (Olympus, Japan) at 1.5, 3, and 4.5 hours after plating.
The total length of tube-like structures formed by LECs in each
well was measured using Image J (NIH). Each treatment was
performed in duplicate and the experiment repeated 3 times using
different batches of LECs (dermis, lung and prostate).
Cell Migration Assay
Migration assays were performed using 48-well microchemo-
taxis chambers (Neuroprobe Inc, MD). Polycarbonate filters (8 mm
pore size; Neuroprobe) were coated with 100 mg/ml collagen type
I (Sigma-Aldrich, MO) overnight at 4uC and air dried. The lower
chamber wells contained serum-free EGMTM-2 MV medium/
0.1% BSA in the presence or absence of VEGF-C, and were
covered by the filter. For inhibitor blocking experiments,
monolayer LECs were serum starved (4 hours), cells were then
lifted and resuspended at 104 cells per 56 ml of EGMTM-2 MV
containing inhibitor or concentration-matched DMSO. After 30-
minute pretreatment, cells were washed in phosphate buffered
saline (PBS) and added to the upper chamber at 104 cells per well.
The cells were allowed to migrate for 6 hours at 37uC, after which
time the filter was fixed with cold methanol and stained with
Quick Dip (Fronine, Australia). Non-migrated cells on the upper
surface of the filter were removed, and the number of migrated
cells was digitally recorded (Leica) and 5 random fields counted
using Image J (NIH). The assays were run in triplicate and
repeated with four different batches of primary prostate LECs.
Proximity Ligation Assay
Cells were plated into 8-well chamber slides (Lab-Tek II, Nalge
Nunc International, Australia) at a density of 26104 cells/well.
The following day, LECs were serum starved (4 hours) prior to
treatment with VEGF-C (100 ng/ml) for 15 minutes. LECs were
then fixed in 10% formalin and subjected to in situ PLA [46]. For
clinical specimens, sections (4 mm) were cut from formalin-fixed
paraffin-embedded tissue.
PLA was performed after antigen retrieval (only in tissue
samples; heat-induced epitope retrieval, 0.01 M citrate buffer
pH 6.0). For cells and tissues, after protein blocking (Olink
Bioscience, Sweden), permeabilization and overnight incubation
with primary antibodies (goat anti-human VEGFR-3 and rabbit
anti-PI3K p85), PLA was performed as per the manufacturer’s
protocol [36] using the PLA PLUS and MINUS probes for goat
and rabbit and the Duolink detection kit 613 (Olink Bioscience).
DAPI was included to stain nuclei and anti-CD31 antibody was
used to identify endothelial cells. For tissue sections, anti-CD31
antibody was replaced with anti-podoplanin antibody to identify
lymphatic vessels. Duolink mounting medium (Olink Bioscience)
was used to coverslip cell/tissue sections and staining evaluated
using a Nikon C1 confocal microscope (Japan). Images show
maximum intensity Z projection. The number of red PLA spots/
nucleus was quantified using Olink Image Analysis software
(Centre for Image Analysis, Uppsala University, Sweden).
Refer to Materials S1 for supplemental methods.
Statistical Analyses
Data obtained in the microchemotaxis assays and Western blots
were analyzed using one-way analysis of variance (ANOVA)
followed by Bonferroni post test for multiple comparisons. The
tube formation assays were analyses using two-way ANOVA. Data
obtained from the in situ PLA was analyzed using t-test. The results
are presented as mean 6 s.e.m., except for PLA data from clinical
specimens where the mean number of PLA signals per lymphatic
vessel is shown for each sample and the group median indicated.
P,0.05 was considered statistically significant. All calculations
were performed using GraphPad Prism 5.0 (GraphPad Software,
CA).
Supporting Information
Figure S1 IMC1121b inhibits VEGFR-2 phosphorylation
induced by VEGF-A in LECs.Western blotting analysis of total
and phosphorylated VEGFR-2 (,190 kDa) in LECs following 15
minute treatment with VEGF-A (25 ng/ml) and 1 hour treatment
withIMC-1121b and hF4-3C5. Total and phospho-VEGFR-2
antibodies were used at 1 mg/ml. Control serum-free vehicle (IgG)
treated LEC lysate is indicated by ‘0’.
(TIF)
Figure S2 VEGF ligands do not induce phosphorylation
of mTOR, whereas VEGF-C induces PI3K and PKC-
dependent Erk1/2 phosphorylation via VEGFR-3 in
LECs. A) VEGF ligands: VEGF-A (100 ng/ml), VEGF-C
(100 ng/ml), VEGF-C156S (250 ng/ml), VEGF-D (250 ng/ml)
and VEGF-E (100 ng/ml) had no stimulatory effect on pS2448
mTOR protein expression. HEK293 cell lysate was used as
positive control, indicated as ‘293’. B, Western blotting analysis of
phosphorylated Erk1/2 in LECs following ligand stimulation:
HGF (400 ng/ml, VEGF-A (100 ng/ml), VEGF-C (100 ng/ml),
VEGF-C156S (250 ng/ml), VEGF-D (250 ng/ml) and VEGF-E
(100 ng/ml); Time course for Erk1/2 phosphorylation in LECs
after VEGF-C (100 ng/ml) and VEGF-A (100 ng/ml) treatment.
C, Concentration-dependent phosphorylation of Erk1/2 in LECs
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after stimulation with VEGF-C for 15 minutes. D, Effect of
inhibition of PI3K (AS252424), Raf/MEK (PD98059), or PKC
(GF109203X) on Erk1/2 phosphorylation in LECs in response to
VEGF-C. E, Phosphorylation of Erk1/2 in LECs following
stimulation with VEGF-A or VEGF-E for 15 minutes at indicated
concentrations. F, Phosphorylation of Erk1/2 in LECs following
stimulation with VEGF-A or VEGF-E at indicated times. G,
Effects of inhibition of VEGFR-3 (hF4-3C5), VEGFR-2 (IMC-
1121b) or VEGFR-1 (IMC-18F1) on LEC Erk1/2 phosphoryla-
tion in response to VEGF-C. Serum-free vehicle (IgG) treated
LEC lysate is indicated by ‘0’ in all blots.
(TIF)
Figure S3 Effect of PLCc1 knock-down on Akt (S473)
phosphorylation in LECs. Silencing PLCc1 in LECs using
siRNA had no effect on Akt (S473) phosphorylation in response to
VEGF-C (100 ng/ml). Non-targeting control (NTC) was used as a
negative control. Control untreated LEC whole cell lysate is
indicated by (WCL). Vehicle-treated LEC is indicated by ‘2’ and
VEGF-C treated is indicated by ‘+’. Densitometry analysis is
shown in italics; where integrated intensity of siRNA PLCc1
lysates was compared to that of the NTC each sample, and then
expressed as fold change in integrated density.
(TIF)
Figure S4 Characterization of isolated LEC by immu-
nocytochemistry. Immunocytochemistry staining shows
VEGFR-3 (left panel, green), LYVE-1 (middle panel, green) and
PROX-1 (right panel, green) staining in human LECs; DAPI staining
is shown in blue. Bar, 50 mm.
(TIF)
Table S1 Lymph node and clinicopathological status of
small cell lung carcinoma patient cohort.
(DOCX)
Materials S1 Supplemental Methods.
(DOC)
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